US pharmaceutical giantis nearing a deal to buy US biotech firm Medivation, which specialises in , for nearly $14 billion, US media reported.
Bloomberg and The Wall Street Journal said the deal could be made public as early as today. The Journal, citing people familiar with the matter, said it could be an all-cash transaction.
Pfizer’s offer for the San Francisco, California-basedMedivation goes far beyond the company’s market value of $11.1 billion. Medivation shares closed at $67.16 in Friday trading.
By purchasing Medivation, Pfizer would add to its portfolio the drug Xtandi, a promising treatment against prostate cancer that analysts estimate will generate some $1.33 billion in annual sales by 2020.